Chronic kidney disease (CKD) is characterized by reduced glomerular filtration rate and increased albuminuria. CKD is more common in diabetes mellitus patients, affecting one patient in every three. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs recently approved for the treatment of type 2 diabetes mellitus. They inhibit the reabsorption of glucose in the early proximal tubule. Studies indicate that these drugs can also improve renal function in CKD patients, making them a promising therapeutic option for such patients. To elaborate further on the potential of SGLT2 inhibitors in CKD, we will be joined by Dr.
Bharat V. Shah on 20 th April 2022 , at 3:00 PM IST . The session will highlight the following points, and more: Chronic kidney disease is usually progressive. Hypertension and proteinuria determine the rate of progression. When ACE inhibitors and ARB…
